Australia's most trusted
source of pharma news
Monday, 27 January 2025
Posted 28 October 2024 AM
Johnson & Johnson has again bulked up its Stelara franchise in another attempt to fend off a growing list of biosimilars of its blockbuster treatment.
The company's new brand Setrelvo, first registered on the ARTG in July in multiple presentations, has now been approved by the TGA as a one-press patient-controlled injector.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.